From research to reality: molecular biomarkers in immuno-oncology – Bristol-Myers Squibb sponsored session

Chair: Gary Middleton, University of Birmingham, UK
Speaker: Mike Hubank, The Royal Marsden, UK
Speaker: John Gosney, Royal Liverpool University Hospital, UK


Room: Alsh

Sponsored by:
Bristol-Myers Squibb

The field of Immuno-Oncology (I-O) has expanded rapidly and now encompasses a range of agents often combined with different treatment modalities across different tumours. However, whilst survival outcomes have improved overall, a significant proportion of patients respond poorly to I-O therapy. Unravelling the inherent biological complexity of the tumour and immune system is crucial to understanding how to improve outcomes for these patients. This includes the identification of biomarkers to select patients for therapy, helping clinicians to optimally employ precision medicine and choose the right treatment for the right patient at the right time.

At this symposium, chaired by Professor Gary Middleton (University of Birmingham), we will consider what the future holds for I-O molecular biomarker research and the practical implications for the NHS as the UK undergoes a genomics transformation. In the first presentation, Professor John Gosney (Royal Liverpool University Hospital) will review biomarkers under current evaluation and the key learnings from those now embedded in clinical practice. In the second presentation, Dr Mike Hubank (The Royal Marsden) will discuss the technical, regulatory and logistical challenges associated with transitioning a novel biomarker into routine diagnostic use.

We hope you will join us for this informative event.

For healthcare professionals and scientific researchers only.
July 2018